A single-arm, proof-of-concept trial has shown the safety and efficacy of ductal lavage as a treatment for idiopathic granulomatous mastitis patients (Manuscript accepted in Journal of Surgical Research 2018). In this multicenter, randomized, open-labeled, non-inferior trial, the investigators are going to enroll eligible granulomatous mastitis patients and randomized them into ductal lavage versus. corticosteroids therapy group. The primary endpoint of this study is the complete clinical response rate at 1 year after the enrollment. The aim of this study is to provide evidence for the management of idiopathic granulomatous mastitis patients .
Non-lactational mastitis (NLM) consists of a broad spectrum of inflammatory breast diseases. Among them, periductal mastitis and idiopathic granulomatous mastitis(IGM) are the most commonly encountered in clinical practice. IGM can be diagnosed when all possible causes of granulomatous diseases (known mycobacterial or fungal infection, Wegener granulomatosis, sarcoidosis, etc.) are excluded. There is no consensus on the standard treatment of IGM patients. Surgery, oral corticosteroids, topical steroids, immunosuppressive therapy, and observation alone were all proposed as the treatment for IGM patients. However, all of the evidences are derived from retrospective studies. In a previous study, the investigators conducted a single-arm, proof-of-concept trial that showed the safety and efficacy of ductal lavage as a treatment for IGM patients. Ductal lavage is possible to spare the patients from corticosteroids therapy and or surgery. To further address this issue, the investigators are going to conduct this multicenter, randomized, open-labeled, non-inferior trial, to compare the efficacy and safety of ductal lavage and corticosteroids therapy. The aim of this study is to provide evidence for the management of IGM patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
140
The patients received ductal lavage and breast massage every other day for two weeks. We used lidocaine (1%) for local anesthesia around the nipple. We used a lacrimal probe to identify 4-5 openings in the lactiferous ducts on the nipple and inserted the infusion cannula (21-23G). A total of 25ml of irrigation solution (5 ml of 2% lidocaine, 40 mg of triamcinolone acetonide, 20 ml of 0.9% saline and 1.0 g of ceftriaxone) was pumped into the ducts over 20-25 minutes. The patient returned to the clinic the next day for breast massage, and the cycle was repeated for two weeks.
Methylprednisolone(Common brand names: Medrol) or prednisone 20-40mg, qd for two weeks, then temper the dose gradually, and then 20mg qd for maintenance (The total duration of the treatment is 6 months).
Jiangmen Maternal and Child Health Care Population & Family Planning Service Center
Jiangmen, Guangdong, China
Lian Jiang People'S Hospital
Lianjiang, Guangdong, China
Complete Clinical Response(cCR)
The proportion of patients that achieve M-score \<=1 at 1 year after the treatment.
Time frame: 1 year since randomization
Time to cCR
The median time to cCR since the randomization.
Time frame: 1 year since randomization
Treatment failure (TF) rate
The proportion of patients with TF at 1 year since the randomization. The TF status is defined as the following: 1. If the patient has M-score\>=6 before randomization, TF is defined as the M-score still remains \>=6 at one month since the randomization. 2. If the patient has M-score between 4 and 5 before randomization, TF is defined as the M-score still remains at \>=4, and never have been lower than 4. 3. If the patient has M-score\<4 before randomization, and never reaches cCR since randomization, and during follow-up, the M-score is found to be \>5 and last for one month.
Time frame: 1 year since randomization
Relapse rate
The proportion of patients that had M-score\>4 among those patients who achieved cCR.
Time frame: 1 year since randomization
Adverse events
Pre-defined and any other unexpected adverse events would be recorded and compared between the two arms.
Time frame: 1 year since randomization
Protocol compliance rate
The proportion of patients who received the treatment protocol.
Time frame: 1 year since randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.